Hakimed: Medical Resources

🗞️ Medical Articles Source: U.S. Department of Health and Human Services (DHHS) Topic: Updated pediatric HIV guidelines recommend dolutegravir-based therapy for neonates The DHHS has released updated Pediatric HIV Guidelines, recommending dolutegravir (DTG)-based antiretroviral therapy as the preferred initial regimen for full-term neonates weighing ≥2 kg. The update also introduces revised recommendations on breastfeeding, infant HIV prophylaxis, and diagnostic testing for HIV-exposed infants. Key changes include birth HIV nucleic acid testing for nearly all exposed infants, continued HIV testing throughout breastfeeding with a final test 3 months after breastfeeding ends, and support for breastfeeding when the parent has maintained viral suppression (<50 copies/mL) for at least 3 months before delivery. The guidelines continue to emphasize INSTI-based regimens because of their strong efficacy and safety. Clinical takeaway: Dolutegravir-based therapy is now the preferred initial ART for eligible neonates, while updated guidance strengthens recommendations on breastfeeding, infant prophylaxis, and HIV testing to improve outcomes in HIV-exposed children. Link: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new @HakimApps_Guideline

🗞️ Medical Articles Source: FDA Topic: FDA approves Lumvoa for thyroid eye disease The FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), a rare autoimmune disorder that can cause proptosis (eye bulging), diplopia (double vision), pain, and vision impairment. Lumvoa is an IGF-1 receptor antagonist indicated for adults with TED regardless of disease activity or duration, making it the first approved therapy with evidence in both active and chronic disease. Approval was based on two phase 3 trials that demonstrated significant improvements in proptosis, diplopia, and other TED symptoms after a 12-week treatment course consisting of five IV infusions. Reductions in eye bulging were observed as early as 3 weeks. Clinical takeaway: Lumvoa offers a new treatment option for both active and chronic thyroid eye disease, providing rapid improvement in eye bulging and double vision with a defined 12-week treatment course. Link: https://investors.viridiantherapeutics.com/news/news-details/2026/Viridian-Therapeutics-Announces-U-S--FDA-Approval-and-Launch-of-Lumvoa-veligrotug-vvze-for-the-Treatment-of-Thyroid-Eye-Disease/default.aspx @HakimApps_Guideline